PMC:7402624 / 58569-58738 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T498","span":{"begin":154,"end":158},"obj":"Body_part"}],"attributes":[{"id":"A498","pred":"fma_id","subj":"T498","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"A key question will be how to identify these patients for selected immune regulatory treatment while avoiding treating patients with already weak T and B cell responses."}

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"1884","span":{"begin":45,"end":53},"obj":"Species"},{"id":"1885","span":{"begin":119,"end":127},"obj":"Species"}],"attributes":[{"id":"A1884","pred":"tao:has_database_id","subj":"1884","obj":"Tax:9606"},{"id":"A1885","pred":"tao:has_database_id","subj":"1885","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A key question will be how to identify these patients for selected immune regulatory treatment while avoiding treating patients with already weak T and B cell responses."}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T903","span":{"begin":0,"end":1},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T904","span":{"begin":152,"end":158},"obj":"http://purl.obolibrary.org/obo/CL_0000236"}],"text":"A key question will be how to identify these patients for selected immune regulatory treatment while avoiding treating patients with already weak T and B cell responses."}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T341","span":{"begin":0,"end":169},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A key question will be how to identify these patients for selected immune regulatory treatment while avoiding treating patients with already weak T and B cell responses."}